CTLA4 and cancer: ICIs act upon T lymphocytes and antigen-presenting cells, versus programmed cell death protein 1 (PD1), programmed cell death protein ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4), deleting the immune tolerance of the T cells against cancer cells [46].